(CLDX) Celldex Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15117B2025

CLDX: Monoclonal, Bispecific, Antibodies, Therapeutic, Treatments

Celldex Therapeutics Inc. (NASDAQ:CLDX) is a biopharmaceutical company focused on developing innovative antibody-based therapies. Their pipeline includes monoclonal and bispecific antibodies designed to target specific pathways in diseases with significant unmet medical needs. This approach is particularly relevant in the biotech sector, where targeted therapies are increasingly valued for their precision and potential to improve patient outcomes.

The companys lead program, CDX-0159, is currently in Phase II trials. This monoclonal antibody targets the KIT receptor tyrosine kinase, which plays a role in various inflammatory and autoimmune conditions. By inhibiting KIT activity, CDX-0159 aims to address diseases where this pathway is dysregulated. This targeted mechanism is a hallmark of modern drug development, allowing for more precise intervention with potentially fewer off-target effects.

Celldex has established a research collaboration and license agreement with Yale University, enhancing their access to cutting-edge scientific research and intellectual property. Such partnerships are crucial in the biotech industry, as they can accelerate drug discovery and development timelines. The company, founded in 1983 and headquartered in Hampton, New Jersey, has built a reputation for leveraging both internal innovation and external collaborations to advance its pipeline.

From a financial perspective, Celldex has a market capitalization of approximately $1.5 billion, reflecting investor confidence in their pipeline and strategy. The price-to-book (P/B) ratio of 1.92 suggests that investors value the companys assets and intellectual property at a premium. The high price-to-sales (P/S) ratio of 150.96 indicates that the market is pricing in significant future revenue expectations, though this also highlights the speculative nature of investing in pre-commercial stage biotech companies.

For investors and fund managers, Celldex represents a play on the growing importance of antibody-based therapies in treating inflammatory, allergic, and autoimmune diseases. The companys focus on bispecific antibodies, which can target multiple pathways simultaneously, is particularly noteworthy given the industrys shift toward combination therapies. However, as with any clinical-stage biotech company, the outcome of ongoing trials will be a critical determinant of long-term success.

Additional Sources for CLDX Stock

CLDX Stock Overview

Market Cap in USD 1,287m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2008-03-10

CLDX Stock Ratings

Growth Rating 29.0
Fundamental -
Dividend Rating 0.0
Rel. Strength -46.2
Analysts 4.58/5
Fair Price Momentum 16.18 USD
Fair Price DCF -

CLDX Dividends

No Dividends Paid

CLDX Growth Ratios

Growth Correlation 3m -93.1%
Growth Correlation 12m -89.3%
Growth Correlation 5y 30.5%
CAGR 5y 45.15%
CAGR/Max DD 5y 0.62
Sharpe Ratio 12m -2.14
Alpha -57.60
Beta 1.248
Volatility 65.26%
Current Volume 579.6k
Average Volume 20d 798.8k
What is the price of CLDX stocks?
As of April 23, 2025, the stock is trading at USD 19.39 with a total of 579,581 shares traded.
Over the past week, the price has changed by +5.55%, over one month by -6.69%, over three months by -20.01% and over the past year by -50.09%.
Is Celldex Therapeutics a good stock to buy?
Neither. Based on ValueRay Analyses, Celldex Therapeutics is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 28.99 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLDX as of April 2025 is 16.18. This means that CLDX is currently overvalued and has a potential downside of -16.55%.
Is CLDX a buy, sell or hold?
Celldex Therapeutics has received a consensus analysts rating of 4.58. Therefor, it is recommend to buy CLDX.
  • Strong Buy: 9
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CLDX stock price target?
According to ValueRays Forecast Model, CLDX Celldex Therapeutics will be worth about 18.1 in April 2026. The stock is currently trading at 19.39. This means that the stock has a potential downside of -6.6%.
Issuer Forecast Upside
Wallstreet Target Price 62.1 220.2%
Analysts Target Price 67.1 246.1%
ValueRay Target Price 18.1 -6.6%